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ABSTRACT
Objectives To estimate the costs and beneﬁts of
clinical pathways incorporating a point of care (POC)
nucleic acid ampliﬁcation test (NAAT) for chlamydia and
gonorrhoea in genitourinary medicine (GUM) clinics
compared with standard off-site laboratory testing.
Method We simulated 1.2 million GUM clinic
attendees in England. A simulation in Microsoft Excel
was developed to compare existing standard pathways of
management for chlamydia and gonorrhoea with a POC
NAAT. We conducted scenario analyses to evaluate the
robustness of the model ﬁndings. The primary outcome
was the incremental cost-effectiveness ratio. Secondary
outcomes included the number of inappropriate
treatments, complications and transmissions averted.
Results The baseline cost of using the point of POC
NAAT was £103.9 million compared with £115.6 million
for standard care. The POC NAAT was also associated
with a small increase of 46 quality adjusted life years,
making the new test both more effective and cheaper.
Over 95 000 inappropriate treatments might be avoided
by using a POC NAAT. Patients receive diagnosis and
treatment on the same day as testing, which may also
prevent 189 cases of pelvic inﬂammatory disease and
17 561 onward transmissions annually.
Discussion Replacing standard laboratory tests for
chlamydia and gonorrhoea with a POC test could be
cost saving and patients would beneﬁt from more
accurate diagnosis and less unnecessary treatment.
Overtreatment currently accounts for about a tenth of
the reported treatments for chlamydia and gonorrhoea
and POC NAATs would effectively eliminate the need for
presumptive treatment.
INTRODUCTION
In England, there were 1 258 706 sexual health
screens performed in genitourinary medicine (GUM)
clinics in 2011, including tests for Chlamydia tracho-
matis (CT) and Neisseria gonorrhoea (NG).1 This
resulted in 100 647 diagnoses of chlamydia and
20 964 of gonorrhoea. Epidemiological treatment, in
which partners of conﬁrmed index cases are given
treatment, was reported for 13 125 cases of chlamydia
and 2162 cases of gonorrhoea. This represents 12%
and 9% of all treatments, respectively, assuming that
all of those diagnosed received treatment. A glossary
of terms is given in box 1. Management of patients
with symptoms indicating possible chlamydia or
gonorrhoea infection usually includes presumptive
treatment for chlamydia prior to conﬁrmed diagnosis
(also called syndromic management).2 3 However,
symptoms can be non-speciﬁc and may also be due to
other infections, for example, Mycoplasma genita-
lium, resulting in unnecessary or potentially less efﬁca-
cious treatment.4 5 Inappropriate or incorrect
treatment can result in (1) unnecessary costs of treat-
ment, (2) continuing symptoms or progression to
sequelae with associated consultation and treatment
costs, (3) selection for the evolution of drug resistance
and (4) delayed appropriate treatment.4–6
Asymptomatic infection is also common and patients
remain untreated until the laboratory diagnosis is
available. Individuals unaware of their infection may
continue to infect partners and risk developing com-
plications during the delay between test and treatment.
Under current best practice, results from off-site
laboratories (standard care) should be available to
clinicians within 7 days or less. A BASHH audit in
2011 surveyed the proportion of GUM clinics that
received chlamydia results within 7 days, the target
being 100%. However, a quarter of clinics reported
that they received 25% of results after 7 days. There
was also variation within and between clinics, for
example, due to laboratory capacity or clinic opening
times.7 Once the clinic receives the test result, the
patient is contacted and advised how to obtain
treatment. The National Chlamydia Screening
Programme audit target is that 50% of chlamydia-
positives should be treated within 14 days; however,
16% of trusts in 2010 failed to meet this target, pri-
marily due to difﬁculties in recontacting patients after
their test or non-attendance.8 Infections may there-
fore remain untreated if patients cannot be contacted
or choose not to return.
There are various technologies employed by
point of care tests (POCTs) including antibody
detection and DNA based methods. Early POC
chlamydia/gonorrhoea tests based on antibody/
antigen binding detection had limited application
due to lower sensitivity and speciﬁcity compared
with nucleic acid ampliﬁcation tests (NAATs) per-
formed in laboratories.9–11 However, new gener-
ation POC NAATs for chlamydia and gonorrhoea
use PCR technology to detect DNA and are
reported to have equivalent performance character-
istics to standard laboratory NAATs. The Cepheid
Xpert CT/NG (Cepheid, Sunnyvale, California,
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USA) is one such test, providing results within 90 min of speci-
men collection.12 13 It is simple to use, does not require highly
skilled staff and requires only a small space in the clinic.
The clinical and economic costs and beneﬁts of POC NAATs
have not yet been fully evaluated for the UK. We present an
early, pragmatic decision analysis of introducing a POC NAAT
for chlamydia and gonorrhoea into GUM clinics compared with
current practice in England. We compare the complete pathway
costs of current practice estimated in four diverse GUM clinics
against a new pathway incorporating a POC NAAT test. The
pathways include testing and treatment costs. This information
can aid services in deciding whether to adopt this new technol-
ogy. We also estimate the number of unnecessary treatments for
chlamydia and gonorrhoea that could be prevented if test, diag-
nosis and treatment are available on the same day. We consider
the potential indirect effects of reducing the time between test
and treatment on preventing onward transmission and progres-
sion to pelvic inﬂammatory disease (PID).
METHODS
Model structure
We developed a decision analytic model in Microsoft Excel
2010 simulating patient pathways to estimate the costs and
beneﬁts of implementing standard care pathways and POC path-
ways including a chlamydia/gonorrhoea POC NAAT.
The model cycle length was 1 day with an overall length of
28 days. The primary outputs were total costs, quality adjusted life
years (QALYs) and incremental cost-effectiveness ratios (ICER).
Description of patient ﬂow through the model
Patient ﬂows are illustrated in ﬁgure 1 and a sample patient ﬂow
is calculated in online supplementary appendix table A1. The
arrows represent the possible transitions at the end of each
model cycle.
All index patients in the model enter the testing pathway.
Under standard care, a proportion of symptomatic patients
are treated presumptively for chlamydia or gonorrhoea at the
time of sexually transmitted infection (STI) screening. The
remaining infected but untreated and/or asymptomatic
patients wait on average 10 days before obtaining treatment at
a second visit. Some treated individuals remain positive due
to treatment failure. Progression to PID and onward transmis-
sion to uninfected partners may occur in positives on days
between test and treatment or following treatment failure. In
the POC pathways, all patients are tested and receive their
result plus appropriate treatment on the same day. As there is
no delay between test and treatment, patients in the POC
pathway only develop complications or transmit to a partner
if they fail treatment.
Asymptomatic partners of chlamydia or gonorrhoea positive
index cases who attend GUM for treatment enter a simpliﬁed
standard care pathway including treatment and test (symptom-
atic partners would be treated as index cases). In the POC
pathway, partners are tested and only positives treated.
Key model assumptions
We assume equivalent test performance for the POCT compared
with standard tests. The new generation POC NAATs appear to
fulﬁl this requirement.12 13 Others have previously investigated
the trade-offs between reduced loss to follow-up versus lower
sensitivity or speciﬁcity and willingness to wait,14 15 so we do
not consider these here. We assume that all tests are in indivi-
duals attending for a new episode and the sample obtained is
appropriate (eg, urine, vulvo-vaginal swab or rectal swab).
Epidemiological and clinical parameters
We modelled a cohort of 1.2 million index patients to simulate
the annual number of STI screens performed at GUM clinics in
England.1
Epidemiological parameters were based on data from the
Genitourinary Medicine Clinic Activity Dataset 2011 (table 1).1
We estimated baseline positivity in men and women of 8.6%
and 7.4% chlamydia and 2.6% and 0.9% gonorrhoea, respect-
ively. We then estimated the distribution of infections between
symptomatic and asymptomatic pathways using a detailed study
of GUM attendees from the MSTIC study.16 We assumed that
all patients reporting symptoms would enter the symptomatic
pathway, regardless of whether their symptoms were indicative
of a chlamydial or gonorrhoeal infection.
We synthesised several aspects of current symptomatic patient
management to make credible estimates of presumptive treat-
ment of positive and negative attendees (see online supplemen-
tary appendix table A2). Available data were used to estimate
the number of contacts attending GUM who would be given
epidemiological treatment in the absence of symptoms.
We estimated the potential for onward transmission of infec-
tion from asymptomatic GUM attendees in the time between
Box 1 Glossary of terms
▸ GLOSSARY
Several terms describe treatment or management of individuals
in whom there is signiﬁcant clinical suspicion that infection may
be present but without conﬁrmed diagnosis. The speciﬁc
meanings may overlap somewhat depending on context and
more than one factor may be present, for example, reported
contact with an infected person plus symptoms.
▸ Presumptive treatment
Treatment given before conﬁrmed diagnosis is made based on
symptoms and clinical evaluation.
▸ Epidemiological treatment
Treatment given based on epidemiological evidence, for
example, reported sexual contact with an infected person, but
could also be a particular risk group during an outbreak
(symptoms usually absent).
▸ Syndromic management
Similar to presumptive treatment, but refers to treatment in the
presence of symptoms or signs indicative of infection.
Both epidemiological treatment and syndromic management are
forms of presumptive treatment.
▸ Overtreatment
Treatment of individuals for an infection who subsequently are
found to test negative for that infection.
▸ Point of care test (POCT)
A test in which the specimen can be processed and results
given to the patients within the same clinic visit, that is, the
specimen is not sent off-site to a laboratory for testing (also
called rapid tests or near-patient tests); may be based on
different methods of detection with variable test performance
characteristics (sensitivity and speciﬁcity).
▸ Point of care nucleic acid ampliﬁcation test (POC NAAT)
This is a POCT that uses NAAT technology. These tests use the
same techniques as current large laboratory based NAAT
platforms, with equivalent performance characteristics, in a
miniaturised computerised system.
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test and treatment based on the frequency of unprotected inter-
course (2/week), transmission probability (5% chlamydia, 10%
gonorrhoea per unprotected sex act) and one partner per index
case and adjusted for the probability that partners were already
infected.17 18 The per day risk of progression from untreated
chlamydia to PID was calculated from a recent evidence synthe-
sis estimate of the overall risk by Price et al.19
Costs and utilities
We take the perspective of a National Health Service (NHS) GUM
clinic deciding whether to implement a chlamydia/gonorrhoea POC
NAAT test. Costs and utilities are summarised in table 2. POCT
pathways represent an alternative streamlined pathway to standard
care, based on same-day diagnosis and treatment; details of both
types of pathways are given in Adams et al.20 The average total cost
Figure 1 Inﬂuence diagrams showing the ﬂow of patients through the model, assuming standard care (A) or point of care (B) pathways for
chlamydia and gonorrhoea testing and treatment for genitourinary medicine clinic attendees. (A) Standard care genitourinary medicine clinic
attendees based on data from Genitourinary Medicine Clinic Activity Dataset (GUMCAD) 2011,1 illustrated using chlamydial infection in men.
Numbers based on a hypothetical cohort of 1000 male attendances and are rounded to the nearest whole number for illustration. Values <1 are not
shown for simplicity. (Note: Attendees who report being a sexual partner of an infected individual are also presumptively treated (partner
treatment). These can be explicitly included in the model as ‘partners’, but are not incorporated in this illustration of ‘index’ individuals, but in the
complete model are added to the total of overtreatment and effective presumptive treatment.) (a) 1000 men attend of whom 350 have any
symptoms at entry into clinic (ie, costed as symptomatic pathway). (b) 956 not treated presumptively, await test result=650 without symptoms
(65%)+306: 87%*350 with symptoms. (c) 44=13%*350 with speciﬁc symptoms are treated presumptively. This assumes 70% of infections are
correctly treated presumptively and that 5% of those not infected (but symptomatic of something else) are overtreated. (d), (e), (k), (n), (o) Show
progression to development of complications, numbers not shown as <1. (e) See (d). (f ) Repeat tests. (g) 881=956–75 (94% of those tested are
negative). (h) 57 (6.0% of those not presumptively treated) are infected=(650*6.9% asymptomatic + 306*4.0% symptomatic) (not chlamydial).
(i). 15 of those presumptively treated (35%*44) were not infected. ( j) 29 of those presumptively treated (65%*44) were infected. (k), (n), (o) All
relate to progression to complications which are rare events dealt with in the model not enumerated for simplicity here (<1). (l) 82 of those
receiving treatment for chlamydia recover and become negative (95% treatment effectiveness). (m) Four fail treatment and remain positive (5%
failure. Note: these would not routinely receive test of cure for chlamydia). From this illustration we can calculate outcomes: (1) Total chlamydial
infections are 86 (8.6%)=29 (presumptive) +57 (wait result). (2). Proportion of infections treated presumptively is 33%=29/86. (3) Number of
unnecessary treatments 15: represents 15%=15/(86+15). (B) Pathway for point of care GUM clinic attendees based on proﬁles from GUMCAD 2011,
illustrated using chlamydial infection in men. Numbers based on attendance of 1000 men and are rounded to nearest whole number for illustration.
Values <1 are not shown for simplicity. (a) 1000 men attend. (b) 914 (91.3% are not infected and do not have complications in the same day). (c)
86 are correctly diagnosed and treated (8.6%). (d), (g), (h) Show progression to development of complications, numbers not shown as <1. (e) 82 of
those receiving treatment for chlamydia recover and become negative (95% treatment effectiveness). (f ) Four fail treatment and remain positive (5%
failure. Note: these would not routinely receive test of cure for chlamydia). From this illustration we can calculate outcomes: (1) Total chlamydial
infections are 86 (8.6%). (2) Proportion of infections treated presumptively is 0. (3) Number of unnecessary treatments is 0.
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for standard care testing pathway was £79.77/£99.38 and for the
new POC testing pathway £75.50/£92.43 in asymptomatic and
symptomatic patients, respectively.20 This includes an assumed
acquisition cost of £13.35 for the standard NAAT and £19.71 for
the POC NAAT, including the sample collection kit for both. The
total testing pathway costs include laboratory time and clinic staff
time to administer and process the test result. The total management
pathway cost includes clinic staff time and treatment costs.
We only considered clinic running costs and excluded any
additional costs of implementing a change in pathway such as
staff training costs or additional quality assurance for perform-
ing tests on-site (eg, lab accreditation).
Table 1 Model input parameters: epidemiological and clinical
Variable
Value Number
Comments Reference/calculationMen Women Men Women
A Number of STI screens 47.3% 52.7% 595 802 662 904 Chlamydia and gonorrhoea test GUMCAD 2011, table 51
B Chlamydial infection 8.6% 7.4% 51 352 49 295 Total diagnoses GUMCAD 2011, table 51
C Gonorrhoeal infection 2.5% 0.9% 14 992 5972 Total diagnoses GUMCAD 2011, table 51
D Proportion symptomatic 35% 48% 208 531 318 194 Symptomatic pathway MSTIC study C Mercer*, personal
communication*16E Proportion asymptomatic 65% 52% Asymptomatic pathway
Chlamydia
F Relative risk (RR) of chlamydia in symptomatic 1.7 0.6 Derived from MSTIC study C Mercer*, personal
communication16
G Proportion of asymptomatic infected 6.9% 9.0% 26 855 31 011 Calculated from RR (row F) Symptomatic positivity =
RRxAsymptomatic positivity
H Proportion symptomatic infected 11.7% 5.7% 24 497 18 284 Calculated from RR (row F)
I Proportion infected symptomatic presumptively
treated
70% 24% 17 148 4388 Estimate (correct presumptive) Assumption
J Proportion uninfected symptomatic presumptively
treated
33% 8% 60 731 21 512 Estimate (overtreatment) Assumption
K Proportion of symptomatic presumptively treated 37% 8% 77 879 25 900 Calculated (Col 4 or 5) =(I+J)/E
L Proportion of presumptively treated infected 22% 17% Calculated (Col 4 or 5) =I/(I+J)
Gonorrhoea
M RR of gonorrhoea in symptomatic 4.5 0.8 Derived from MSTIC study C Mercer, personal
communication16
N Proportion asymptomatic infected 1.1% 1.0% 4368 3406 Calculated using RR (row M)
O Proportion symptomatic infected 5.1% 0.8% 10 624 2566 Calculated using RR (row M)
P Proportion infected symptomatic presumptively
treated
90% 50% 9562 1283 Correct presumptive Assumption
Q Proportion uninfected symptomatic presumptively
treated
2% 3% 3958 9469 Overtreatment Broadly consistent with
GUMCAD1†
R Proportion of symptomatic presumptively treated 6% 3% 13 520 10 752 Calculated (Col 4 or 5) =(P+Q)/E
S Proportion of presumptively treated infected 71% 12% Calculated (Col 4 or 5) =P/(P+Q)
Other parameters
T Proportion of GUM attendees who present as
contacts of infected who are presumptively treated
100% 100% BASHH guidelines2 3
U Transmission probability per sex act chlamydia
(no condom)
5% 5% During unprotected sex acts in
2 weeks following GUM visit
Conservative estimate17
V Transmission probability per sex act gonorrhoea
(no condom)
10% 10% Conservative estimate18
W Number of unprotected sex acts per week after
GUM visit
2 2 Conservative estimate
X Progression to PID from chlamydia (per day) 0 0.00035 Estimated from Bayesian evidence
synthesis19‡
Y Progression to PID from gonorrhoea (per day) 0 0.00035 Assumed same as chlamydia
Z Treatment effectiveness 95% 95% Estimate Guidelines require >95%
efficacy2 3
AA Probability that partner of index is chlamydia positive 0.4 0.4 Conservative assumption Assumption
AB Probability that partner of index is gonorrhoea
positive
0.4 0.4 Conservative assumption Assumption
*We use RR to adjust the fraction of infections occurring in symptomatic or asymptomatic pathways but retained the overall prevalence as observed in GUMCAD. RR in symptomatic
patients was calculated based on proportion infected in those reporting symptoms at attendance in MSTIC (533 men, 731 women)15 (unpublished data kindly provided by Cath Mercer,
UCL). The RR was then applied to the GUMCAD data to distribute infections between those symptomatically and asymptomatically infected.
†The proportion of those uninfected who get treated presumptively was calculated such that the total amount of presumptive treatment is broadly consistent with reported
epidemiological treatment in GUMCAD. Also see figure 1 for illustration of how these parameters play out in the influence diagram.
‡Price et al19 recently synthesised evidence to calculate the overall progression rate from untreated chlamydia to PID as 0.16 (0.06 to 0.25 CIs). Assuming the mean duration of
untreated chlamydia is 493 days and a constant risk of progression, this equates to a risk of 0.00035 per day, by rearranging the formula: y=1−(1−x)493 where y is the total incidence
(y=0.16) to calculate x, the daily probability of progression to PID.
GUMCAD, Genitourinary Medicine Clinic Activity Dataset; PID, pelvic inflammatory disease; STI, sexually transmitted infection.
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Utility estimates were obtained from published literature or
expert opinion of the authors if no data were available (table 2).
We assumed at baseline that patients did not have any disutility
associated with anxiety while waiting for test results or from
negative results.
Outcome measure
The primary outcome is the total cost per QALY gained, expressed
as an ICER between standard care and POCT pathways
(costPOCT−coststandard care)/(QALYPOCT−QALYstandard care). The sec-
ondary outcomes were number of overtreatments prevented,
onward transmissions prevented and PID cases prevented.
Scenario and sensitivity analyses
We conducted scenario analyses to evaluate the robustness of
the model ﬁndings in which we varied different key parameter
values. We considered ﬁve primary scenarios which would tend
to favour standard care ((1) shorter time to treatment, (2) no
progression to PID or onward transmissions, (3) lower baseline
prevalence, (4) higher POC test acquisition cost) or where an
uncertain parameter estimate could potentially have a large
effect ((5) patients experience disutility while awaiting test
results). Additional scenarios are detailed in online supplemen-
tary appendix table A3. We performed a univariate sensitivity
analysis, varying the POC NAATacquisition cost.
RESULTS
The POCT pathway was £11.7 million cheaper and increased
QALYs by 46 compared with standard care at baseline, shown in
table 3. Since the POC NAAT pathway dominates, the ICER is
not meaningful and is not presented. The total cost of providing
chlamydia/gonorrhoea testing and treatment for 1.2 million
GUM attendees in standard care is £115.6 million and for the
POC pathway is £103.9 million. The POC NAAT pathway
could prevent 17 561 onward transmissions, 189 cases of PID
and more than 95 000 overtreatments per year under baseline
assumptions (table 3). If the acquisition cost of the POC NAAT
is more than £10 higher than baseline (ie, £29.73 instead of
£19.73) then the POC pathway becomes more expensive than
current standard care (see online supplementary appendix
ﬁgure A1).
In scenario 1, standard care is assumed to deliver treatment to
all patients in 4 days. This reduces the number of outcomes
averted, but does not inﬂuence the costs. In scenario 2 the POC
has lower cost, but does not result in prevention of sequelae or
transmission. If prevalence is lower than currently assumed then
the POC test prevents more unnecessary treatment but the
overall difference in costs is reduced (scenario 3). If the POC
NAAT is more expensive (scenario 4) then standard care is
cheaper overall, but POC still reduces overtreatment. In this
case, the total cost of the POC pathway is £116.1 million com-
pared with £115.6 million for standard care. The total cost of
testing varies linearly with increasing POC NAAT test cost
(from £9.73 to £39.73, baseline £19.73), shown in univariate
sensitivity analysis in online supplementary appendix ﬁgure A1.
If patients experience anxiety during the wait for results then
the POC NAAT compared with standard care can result in 2536
QALYs gained compared with 47 in the baseline scenario (scen-
ario 5).
Additional scenarios are given in the online supplementary
appendix table A3. If the underlying prevalence is higher, or
fewer true infections are treated presumptively, the POCT test is
more cost-effective (scenarios 6 and 7). Similarly, if there is
more overtreatment or more preventable transmissions or seque-
lae this also favours the POC NAAT (scenarios 8–11).
If 40% of partners are infected, then 60% of partners treated
presumptively receive unnecessary treatment. Epidemiological
treatment of partners under standard care costs £1.7 million
and POC costs £0.95 million (see online supplementary appen-
dix table A4). Infection positivity among partners does not
affect the cost of the standard care pathway (since all are
treated) but the cost of the POC pathway increases with
Table 2 Model input parameters: costs and utilities
Costs SC £ POCT £ Notes Reference
Asymptomatic testing* 79.77 75.50 SC based on current costs, POCT average of two clinic pathways
(£77.42 and £73.57)
Adams et al20
Symptomatic testing* 99.38 92.43 SC based on current costs, POCT average of two clinic pathways
(£100.39 and £84.46)
Chlamydia management, primary 34.89 34.89 Adams et al20
Chlamydia management, additional 24.99 24.99 Adams et al20
Gonorrhoea management, primary 112.05 117.94 Includes the first treatment (primary) and a test of cure (primary) Adams et al20
Gonorrhoea management, additional 101.86 107.75 Includes the first treatment (additional) and a test of cure (primary) Adams et al20
Gonorrhoea management, second line 41.07 41.07 Second line treatment is cefixime plus azithromycin Adams et al20
BASHH2
Treatment for PID 163.00 163.00 Weighted average of treatment in general practice, GUM and other settings Aghaizu et al21
Chlamydia/gonorrhoea testing* 45.34 38.76 Reduced pathway used for partner testing only Adams et al20
Utilities
Pretest status unknown 1.00 Assume otherwise healthy population Assumption
Post-test status unknown 1.00 Assume no anxiety while waiting for result Assumption
Symptomatic 0.84 Average for men/women for chlamydia/gonorrhoea Institute of Medicine22
Infection positive 0.85 Assumed to be slightly decreased due to anxiety from being positive Assumption
Complications 0.80 Mean of values for PID Smith et al23
Infection negative 1.00 Assume otherwise healthy population Assumption
*All testing pathways include an acquisition cost of test and sample collection kit: standard care costs £12 for the test plus £1.35 for the sample collection kit; POC costs £18 for the
test plus £1.71 for the sample collection kit.
GUM, genitourinary medicine; PID, pelvic inflammatory disease; POCT, point of care test; SC, standard care.
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increasing positivity, due to increased treatment costs. The great-
est difference in cost between the POC and standard care path-
ways occurs when the proportion infected of those
epidemiologically treated is lowest.
DISCUSSION
In the baseline model scenario, the POCT pathway dominates
the standard care test pathway and will save an estimated £11.7
million annually in GUM and gain 46 QALYs overall. The
POCT pathway includes a more expensive test, but less clinician
time. Even making pessimistic assumptions that the POC will
not prevent any overtreatment, complications or transmissions,
the POC pathway dominates. Same day diagnosis and treatment
could prevent over 95 000 unnecessary treatments per year.
The strengths of this paper are that the pathway costs are
based on a recent study and patient infection characteristics and
management derived from national data.20 The model and cost
estimates are for England, where patients typically have to wait
to see a clinician, and tests and treatment are provided free of
charge by the NHS.
We considered costs from an NHS GUM clinic perspective
and did not consider patient costs, for example, returning for
treatment. Additional costs may also be incurred by clinics in
changing between pathways, for example, developing new
testing protocols, staff training and laboratory accreditation;
these are not considered here. We did not consider the potential
effect of large changes in clinic demand due to the availability
of a new POC test as the impact is not yet known. Qualitative
research is required to assess the likely impact on clinic attend-
ance for example, testing more ‘worried well’ or increasing
testing in hard to engage groups. The evidence for patient
experience of waiting for GUM test results in the UK setting is
not well characterised. One study of chlamydia screening, the
Class study, reported a reduction in anxiety on receipt of a nega-
tive test for women and on submitting a sample for testing for
men.24 In our model, if waiting for 10 days is associated with
anxiety (0.95 utility) then there could be a much greater QALY
gain from early diagnosis of 2536 QALYs. Studies are required
to evaluate the potential impact of POC NAAT tests on patient
experience.
Some model parameters are not well estimated in the litera-
ture. A detailed breakdown of current patient management was
not available from national data to link initial presentation and
management with test results. The estimates of presumptive
treatment are consistent with data on the number of diagnoses
of non-speciﬁc genital tract infection, non-gonorrhoeal/non-
chlamydial PID or epididymitis (see online supplementary
appendix table A2). However, this leads to an overestimate of
overtreatment if these related diagnoses were not presumptively
treated for chlamydia. Conversely, other presenting conditions
might also be treated presumptively leading to underestimation
of presumptive treatment. Treatment regimens for chlamydia
have previously been considered effective against other infec-
tions, but recent ﬁndings suggest that alternative treatments may
be preferable if chlamydia and gonorrhoea can be ruled out ini-
tially.2–6
We only considered the immediate complication of PID in
women as this has been shown to have the greatest effect on
cost and may occur in the time period considered in our ana-
lysis.25 Other complications may also result from infection
with chlamydia or gonorrhoea, for example, epididymitis in
men. If earlier treatment prevents other complications (not
Table 3 The cost, quality adjusted life years, transmission to partners, PID cases and overtreatment in standard care compared to point of care
tests for chlamydia and gonorrhoea in genitourinary medicine clinics in the UK: baseline and scenario analyses results.
Scenario
Baseline
1 Short time
to treat
2 Low
prevalence
3 No PID or onward
transmission
4 High POC
NAAT test cost
5 Wait for test
anxiety
See tables 1 and 2 for
full baseline parameter
list
Rx time=4 days
(baseline: 10 days)
CT=4.3% M,
3.7% F
NG=1.3% M,
0.5% F (baseline:
CT=8.6% M,
7.4% F,
NG=2.5% M,
0.9% F)
Transmission probability 0%
for CT/NG, PID=0
(baseline: 5% CT, 10% NG
per unprotected act,
PID=0.00035 per day)
POC NAAT test
cost=£29.73
(baseline
£19.73)
Utility post-test
status
unknown=0.95
(baseline: 1)
SC
Cost £115 627 887 £115 613 353 £112 997 661 £115 595 915 £115 627 887 £115 627 887
QALY 184 012 184 013 184 036 184 015 184 012 181 523
Transmissions 17 561 7434 8811 – 17 561 17 561
PID 223 132 119 – 223 223
Overtreatment 95 382 95 382 100 278 95 431 95 382 95 382
POC
Cost £103 873 872 £103 873 872 £101 452 506 £103 868 307 £116 078 901 £103 873 872
QALY 184 059 184 059 184 084 184 059 184 059 184 059
Transmissions – – – – – –
PID 34 34 17 – 34 34
Overtreatment – – – – – –
Difference (POC-SC)
Cost −£11 754 015 −£11 739 481 −£11 545 155 −£11 727 608 £451 014 −£11 754 015
QALY 46 45 48 44 46 2536
Transmissions −17 561 −7434 −8811 0 −17 561 −17 561
PID −189 −98 −102 0 −189 −189
Overtreatment −95 382 −95 382 −100 278 −95 431 −95 382 −95 382
CT, Chlamydia trachomatis, NAAT, nucleic acid amplification test; NG, Neisseria gonorrhoea, PID, pelvic inflammatory disease, POC, point of care; QALY, quality adjusted life year; Rx,
treatment; SC, standard care.
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just PID),26 this would increase the POC NAAT
cost-effectiveness.
Cost implications may be different in countries with other health-
care models. Huang et al27 also found that in the USA, a POCTwas
cost-effective in comparison with standard care, even without includ-
ing additional indirect beneﬁts such as reduced overtreatment and
reduced transmission potential. They found that POCT sensitivity,
proportion of women willing to wait for test results and the POCT
costs were the most inﬂuential parameters in the model. In contrast,
we assumed that all patients are willing to wait for a result, and a
recent UK study found that 75% of women were prepared to wait
between 30 min and 2 h and 18%were prepared to wait over 2 h.28
We assumed that both the standard care and the POCTs had
equivalent performance characteristics. If this is not achieved in
practice then not all the beneﬁts of early diagnosis are realised.
POCTs test characteristics have been previously modelled exten-
sively, showing that sensitivity is a key factor.14 Gift et al15 have
demonstrated that test sensitivity could be balanced against
return rates for treatments. A systematic review was conducted in
2010 and others have concluded that a chlamydia/gonorrhoea
POCTwith sufﬁciently good performance for routine clinical use
was not currently available.9 10 29 However, these papers did not
include new generation POC NAAT tests. The chlamydia/gonor-
rhoea POC NAAT developed by Cepheid has shown equivalent
performance to standard NAAT tests in early trials.12 13 27 It has
received CE marking and FDA approval, and is being marketed
for use in Europe, North America, the Middle East and Africa.
Several other tests will likely emerge in the near future. The new
generation POC NAAT tests need to be evaluated in independent
randomised controlled trials, compared head to head in routine
practice and included in an updated systematic review.
This study indicates that introducing a chlamydia/gonorrhoea
POC NAAT could be cost saving, subject to our assumptions about
the data and clinical pathway. The introduction of such tests to
GUM clinics may also beneﬁt patients by providing a more accurate
and timely diagnosis with potentially better treatment outcomes
and fewer unnecessary treatments. The study highlights that many
symptomatic men and women currently receive treatment using an
antibiotic primarily intended for treating chlamydia when this infec-
tion may not be present, and for which better treatments may be
available. Additional national guidance will be required to enable
clinics make informed choices about whether and how to imple-
ment new pathways with chlamydia/gonorrhoea POC NAATs in the
future. Once up and running, POC NAATs for chlamydia and gon-
orrhoea in English GUM clinics could save the NHS money.
Key messages
▸ Point of care test pathways could be implemented in
genitourinary medicine clinics with minimal increases in cost
or could be cost saving once established.
▸ Presumptive or epidemiological treatment of chlamydia and/
or gonorrhoea accounts for a large number of suboptimal
and unnecessary antibiotic prescriptions.
▸ Additional national guidance is required to enable clinics to
make informed choices about whether and how to
implement new pathways in the future.
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